Vitasora Health Expands Evolent Care Partnership to Drive US Growth Strategy
Vitasora Health (ASX: VHL) has expanded its partnership with Evolent Care Partners, extending its Connected Care services across the US following a successful pilot program in Hawaii.
The agreement positions Vitasora to deliver remote patient monitoring and chronic care management to between 20,000 and 30,000 patients from 2026 under the Medicare Shared Savings Program.
Chief executive officer Mr Marjan Mikel said the nationwide rollout represented a highly significant growth milestone, with projected annual recurring revenue of between US$12 million and US$18m as additional states come online.
Scaling Connected Care Nationwide
Under the expanded program, Vitasora will work across as many as 15 mainland states, supporting thousands of independent primary care physicians within the Evolent and Privia Health networks.
The expansion follows Evolent Health’s decision to divest Evolent Care Partners to Privia Health, a NASDAQ-listed organisation managing about 1.5 million patients and one of the highest-performing accountable care portfolios in the country.
Vitasora expects this integration to provide a larger platform for scaling its Connected Care model nationally.
Mr Mikel said the Hawaii pilot demonstrated the company’s ability to improve patient outcomes and provider satisfaction at scale.
“While there is still work ahead to ensure the seamless rollout of this clinical program across the US, the Evolent expansion represents a highly significant revenue opportunity for Vitasora that is pivotal to our path to profitability and further substantial revenue growth in 2026,” he said.
Pathway To Profitability Strengthened
The US expansion follows confirmation that Vitasora has received A$2.43m in cleared funds from its cornerstone investor as part of a A$6.75m commitment at $0.03 per share.
This finalises a total $11m capital raise, with the remaining funds due by mid-November.
The cornerstone investment ensures Vitasora remains fully funded to deliver its growth objectives and achieve forecast cash-flow breakeven.
Mr Mikel said the capital inflow would support the expansion of key US partnerships, including Tampa Family Medical Centers, and Iris Healthcare, while underpinning negotiations with additional healthcare groups.
“Our operational momentum continues to build, [and] we are confident our execution capability will see us achieve profitability in Q4 FY2026,” he said.